Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Noncanonical CDK4 signaling rescues diabetes in a mouse model by promoting β cell differentiation
Rachel E. Stamateris, … , Sushil G. Rane, Laura C. Alonso
Rachel E. Stamateris, … , Sushil G. Rane, Laura C. Alonso
Published September 15, 2023
Citation Information: J Clin Invest. 2023;133(18):e166490. https://doi.org/10.1172/JCI166490.
View: Text | PDF
Research Article Endocrinology Metabolism

Noncanonical CDK4 signaling rescues diabetes in a mouse model by promoting β cell differentiation

  • Text
  • PDF
Abstract

Expanding β cell mass is a critical goal in the fight against diabetes. CDK4, an extensively characterized cell cycle activator, is required to establish and maintain β cell number. β cell failure in the IRS2-deletion mouse type 2 diabetes model is, in part, due to loss of CDK4 regulator cyclin D2. We set out to determine whether replacement of endogenous CDK4 with the inhibitor-resistant mutant CDK4-R24C rescued the loss of β cell mass in IRS2-deficient mice. Surprisingly, not only β cell mass but also β cell dedifferentiation was effectively rescued, despite no improvement in whole body insulin sensitivity. Ex vivo studies in primary islet cells revealed a mechanism in which CDK4 intervened downstream in the insulin signaling pathway to prevent FOXO1-mediated transcriptional repression of critical β cell transcription factor Pdx1. FOXO1 inhibition was not related to E2F1 activity, to FOXO1 phosphorylation, or even to FOXO1 subcellular localization, but rather was related to deacetylation and reduced FOXO1 abundance. Taken together, these results demonstrate a differentiation-promoting activity of the classical cell cycle activator CDK4 and support the concept that β cell mass can be expanded without compromising function.

Authors

Rachel E. Stamateris, Huguet V. Landa-Galvan, Rohit B. Sharma, Christine Darko, David Redmond, Sushil G. Rane, Laura C. Alonso

×

Figure 4

CDK4 suppresses starvation-induced FOXO1 activity in mouse islet cells.

Options: View larger image (or click on image) Download as PowerPoint
CDK4 suppresses starvation-induced FOXO1 activity in mouse islet cells.
...
(A) Dispersed mouse islet cells cultured in islet complete medium (15 mM glucose, 10% FBS, control) or starve medium (2 mM glucose, 0% FBS) for 16 hours were fixed, immunostained for FOXO1 (red), insulin (green), and Dapi (blue), and imaged by confocal microscopy. (B–G) Dispersed mouse islet cells transduced with the indicated adenoviruses were cultured as in A, then lysed for qPCR for known FOXO1 target genes (n ≥ 12) (B), proliferation markers (n ≥ 12) (C), and β cell differentiation genes (n ≥ 12) (D). (E–G) Transduction with CDK4 activators (Ad-h-CDK4, Ad-m-cyclinD2, and Ad-h-Cdk4+Ad-m-cyclinD2), or CDK4 inhibitor (Ad-m-p16) showed that activating CDK4 rescued abundance of proliferation markers (n ≥ 7) (E), rescued 2 of 3 FOXO1 targets (n ≥ 8) (F), and rescued Pdx1 (n ≥ 8) and Neurod1 (n ≥ 8) expression but not Mafa (n ≥ 8). Nkx6.1 (n ≥ 5) and Ngn3 (n ≥ 5) were not changed by starvation or CDK4 overexpression (G). Data in B–D are the controls from E–G, presented separately for clarity. (H and I) (n ≥ 4) Ad-h-CDK4 or Ad-m-cyclinD2 increased phosphorylation of FOXO1 in dispersed mouse islet cells exposed to starve conditions (H), but Ad-m-p16 did not, quantified in (I). Confocal microscopy (J) with quantification of the percentage β cells with nuclear FOXO1 showed nuclear FOXO1 was variably reduced by CDK4 activation. Top and bottom panels show 2 different biological replicates illustrating variability of nuclear FOXO1 abundance. Grayscale panels represent red-channel (FOXO1) immunofluorescence. Dashed lines represent mean starve control condition. Images in A and J are representative of n ≥ 4 experiments. Original magnification, ×400 (A and J). Statistics by t test (B-D) or 1-way ANOVA (E–I) with Tukey’s posthoc test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts